Motor signs during the course of Alzheimer disease

N Scarmeas1, G M Hadjigeorgiou, A Papadimitriou

  • 1Cognitive Neuroscience Division, Taub Institute for Research in Alzheimer's Disease and the Aging Brain, Gertrude H. Sergievsky Center, and Department of Neurology, New York, NY 10032, USA. ns257@columbia.edu

Neurology
|September 29, 2004
PubMed
Abstract

Insights

Motor signs (MOSIs) are common in Alzheimer disease (AD). Most MOSIs progress rapidly, but tremor is less frequent and slower progressing in AD patients.

Area of Science:

  • Neurology
  • Neuroscience
  • Geriatrics

Background:

  • Motor signs (MOSIs) are frequently observed in Alzheimer disease (AD).
  • MOSIs may correlate with cognitive decline, mortality, and healthcare costs in AD patients.

Purpose of the Study:

  • To characterize the progression of individual motor signs in Alzheimer disease.
  • To identify predictors for the onset of specific motor signs in AD.

Main Methods:

  • A longitudinal cohort study followed 474 early-stage AD patients for up to 13.1 years.
  • Motor signs were assessed using the Unified Parkinson's Disease Rating Scale.
  • Cox models were employed to identify predictors of MOSI incidence.

Main Results:

  • At least one MOSI was present in 13% initially and 36% by the final evaluation.
  • Annual progression rates for speech/facial expression, rigidity, posture/gait, and bradykinesia ranged from 2.45% to 4%.
  • Tremor was less common (4% to 7%) and progressed slower (0.75%/year).

Conclusions:

  • The majority of motor signs manifest frequently and advance rapidly in Alzheimer disease.
  • Tremor represents an exception, appearing less often and progressing at a slower rate in AD.

Related Concept Videos

Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Alterations in Muscle Tone lll01:11

Alterations in Muscle Tone lll

Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...